Tags

Type your tag names separated by a space and hit enter

Insulin lispro, a new insulin analog.
Pharmacotherapy. 1998 May-Jun; 18(3):526-38.P

Abstract

Insulin lispro is a rapid-acting insulin analog to regular insulin. Inversion of the proline-lysine amino acid sequence at positions 28 and 29 on the B chain is responsible for its more rapid absorption, faster onset, and shorter duration of action compared with regular insulin. The fast onset of action allows for greater flexibility in dosing and mealtime scheduling. Insulin lispro provides equivalent or slightly improved glycemic control in patients with types I and II diabetes mellitus compared with regular insulin, without subsequent increases in hypoglycemic episodes. It also results in greater reduction in postprandial blood glucose excursion than regular insulin. Compared with other insulins, insulin lispro represents a more physiologic approach to exogenous insulin therapy.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Kucera ML
Veterans Affairs Medical Center, Amarillo, Texas, USA.
Graham JP
No affiliation info available

MeSH

Blood GlucoseDiabetes MellitusDietDrug CostsFemaleHumansHypoglycemic AgentsInsulinInsulin LisproPostprandial PeriodPregnancyQuality of LifeRandomized Controlled Trials as Topic

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9620104

Citation

Kucera, M L., and J P. Graham. "Insulin Lispro, a New Insulin Analog." Pharmacotherapy, vol. 18, no. 3, 1998, pp. 526-38.
Kucera ML, Graham JP. Insulin lispro, a new insulin analog. Pharmacotherapy. 1998;18(3):526-38.
Kucera, M. L., & Graham, J. P. (1998). Insulin lispro, a new insulin analog. Pharmacotherapy, 18(3), 526-38.
Kucera ML, Graham JP. Insulin Lispro, a New Insulin Analog. Pharmacotherapy. 1998 May-Jun;18(3):526-38. PubMed PMID: 9620104.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin lispro, a new insulin analog. AU - Kucera,M L, AU - Graham,J P, PY - 1998/6/10/pubmed PY - 1998/6/10/medline PY - 1998/6/10/entrez SP - 526 EP - 38 JF - Pharmacotherapy JO - Pharmacotherapy VL - 18 IS - 3 N2 - Insulin lispro is a rapid-acting insulin analog to regular insulin. Inversion of the proline-lysine amino acid sequence at positions 28 and 29 on the B chain is responsible for its more rapid absorption, faster onset, and shorter duration of action compared with regular insulin. The fast onset of action allows for greater flexibility in dosing and mealtime scheduling. Insulin lispro provides equivalent or slightly improved glycemic control in patients with types I and II diabetes mellitus compared with regular insulin, without subsequent increases in hypoglycemic episodes. It also results in greater reduction in postprandial blood glucose excursion than regular insulin. Compared with other insulins, insulin lispro represents a more physiologic approach to exogenous insulin therapy. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/9620104/Insulin_lispro_a_new_insulin_analog_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0277-0008&date=1998&volume=18&issue=3&spage=526 DB - PRIME DP - Unbound Medicine ER -